ArticleIBRO neuroscience reports2025
Development & validation of a simple, sensitive, robust, reproducible & economical spectrofluorimetric method for estimation of taurine in novel chewable gel.
Article in IBRO neuroscience reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Taurine, known as 2-aminoethanesulphonic acid, is a sulfur-containing β-amino acid not incorporated into proteins. However, it takes part in biochemical reactions of significant importance, such as conjugation with bile acids to form bile salts essential for fat absorption, cell membrane stabilization, antioxidation, detoxification, osmoregulation, neuromodulation, and brain and retinal development. Objective: To increase its dissolution and absorption rate for early onset of action, we developed a medicated gel formulation of taurine. Chewable gels are suitable dosage forms for pediatric, geriatric, and dysphagic patients. The current research aims to develop a simple, sensitive, and reproducible spectrofluorometric method for determining taurine in chewable gel. Method: A spectrofluorimetric method was developed, and the determination of taurine was based on Hantzsch condensation synthesis, and the fluorescence intensity was measured at emission wavelength (λem) of 474 nm after excitation (λex) at 416 nm. The spectrofluorimetry method for taurine was validated according to the Q2B(R1) ICH guideline for method validation and validated for linearity, LOD, LOQ, interday and intraday precision, accuracy, and robustness. Results: The calibration curve was linear in a 1.5-50 µg/ml concentration range. The correlation coefficient (r2) was found to be 0.994. The % RSD values of intra-day precision lie between 0.11 and 0.09; for inter-day precision, it was found to be between 0.09 and 0.11; in both cases, it is less than 2 %. The percentage accuracy study was between 91.81 and 99.93 with a % RSD value of 0.078, less than 2 %. LOD & LOQ values have been mathematically calculated to 4.03 µg/ml and 12.23 µg/ml, respectively. The method was precise, accurate, and robust. Conclusion: All validation parameters were found to be within their acceptable limits. Thus, the developed spectrofluorimetric method of taurine is economical, fast, and robust. Further, this method was utilized to estimate taurine content uniformity in chewable gel for in-vitro release studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.